PDF(Pubmed)
Abstract：
Background COVID-19, caused by SARS-CoV-2, led to a global pandemic necessitating urgent vaccine development and deployment. By the end of 2020, several vaccines had reached their clinical trial endpoints. India, leveraging its pharmaceutical prowess, developed two primary vaccines: CoviShield® and Covaxin®. Despite the availability of these vaccines, vaccine hesitancy became a notable challenge. This study aimed to assess the correlation between vaccination status and lung involvement in COVID-19 patients, aiming to fortify trust in vaccines and enhance vaccine uptake in India. Methods This retrospective cross-sectional study analyzed data from 272 patients treated at a designated COVID-19 Care Center in Chennai, India, from May to July 2021. Patients were divided into vaccinated and unvaccinated groups, with vaccinated individuals further categorized based on the type and dose of vaccine received (CoviShield® or Covaxin®). Lung involvement was assessed through CT chest scans, and statistical analyses were performed to compare the severity of lung involvement across different groups. Results The vaccinated group demonstrated significantly lower mean lung involvement (28%) compared to the unvaccinated group (34.8%). Within vaccinated individuals, no significant differences were observed between different vaccine types and doses, suggesting a generalized protective effect of COVID-19 vaccination against severe lung involvement. Conclusion Vaccination against COVID-19 significantly reduces the severity of lung involvement among patients, irrespective of the vaccine brand or dose. This study reinforces the importance of vaccination in mitigating the impact of COVID-19 and supports ongoing vaccination efforts.
摘要：
背景由SARS-CoV-2引起的COVID-19导致了全球大流行，迫切需要疫苗的开发和部署。到2020年底，几种疫苗已达到临床试验终点。印度,利用它的制药能力，开发了两种主要疫苗：CoviShield®和Covaxin®。尽管有这些疫苗，疫苗犹豫成为一个显著的挑战。这项研究旨在评估COVID-19患者的疫苗接种状态与肺部受累之间的相关性，旨在加强对疫苗的信任，并提高印度的疫苗使用率。方法这项回顾性横断面研究分析了在钦奈指定的COVID-19护理中心接受治疗的272例患者的数据，印度,2021年5月至7月。将患者分为接种疫苗组和未接种疫苗组，接种疫苗的个体根据接种疫苗的类型和剂量进一步分类（CoviShield®或Covaxin®）。通过CT胸部扫描评估肺部受累，并进行统计学分析,比较不同组肺部受累的严重程度.结果与未接种组(34.8%)相比,接种组显示出显著较低的平均肺受累(28%)。在接种疫苗的个体中，不同疫苗类型和剂量之间没有观察到显著差异，提示COVID-19疫苗对严重肺部受累具有普遍的保护作用。结论接种COVID-19可显著降低患者肺部受累的严重程度,无论疫苗品牌或剂量。这项研究加强了疫苗接种在减轻COVID-19影响方面的重要性，并支持正在进行的疫苗接种工作。
